Type 2 Diabetes

During AAPA 2024, a group of session presenters provide recommendations for the next year's agenda based on trends and development.

Peterson reviews the gastric and hormonal events linked to drugs like tirzepatide, before considering whether incretin therapies will help to finally embrace obesity as the medical condition it is.

With agents like semaglutide and tirzepatide becoming household drug names, Peterson discusses the short-term future of incretin drug development.

New analyses show adults aged ≥65 years old are at about 30% increased risk of hypertension when diagnosed with diabetes mellitus.

Medical experts offer a comprehensive overview of the pathophysiology of hypercortisolism, detailing its impact on β-cell dysfunction and reduced insulin sensitivity, and discuss the potential role of GLP-1 treatment in managing the condition.

Ralph DeFronzo, MD, leads a discussion on the evolving perception of autonomous adrenal hypercortisolism, highlighting that its prevelance is significantly greater than previously understood.

The analysis of NHANES data revealed almost 90% of adults meet the criteria for stage 1 or greater CKM syndrome, consistent from 2011-2020.

The panel emphasizes the importance of early identification of patients based on subgroups, such as those with difficult-to-control diabetes, hypertension, and bone issues, highlighting that the inability to lower a patient's insulin dosage is a significant risk factor for hypercortisolism.

Christopher Lucci, MD, reviews the current diagnostic tests for hypercortisolism, which include the Dexamethasone Suppression Test, DHEA level tests, and ACTH assessments.

The HCPLive Endocrinology month in review for April 2024 spotlights SURMOUNT-OSA, STEP HFpEF DM, new ACP guidelines for T2D, and more!

A retrospective study challenges preoperative withholding of GLP-1 RAs in diabetes patients undergoing surgery, citing no increased risk of postoperative respiratory complications.

In this episode, hosts break down the latest type 2 diabetes recommendations from the American College of Physicians and offer their perspective on second-line therapies in T2D.

The American College of Physicians released new recommendations for the management of type 2 diabetes with inadequate glycemic control using metformin or other first-line therapies.

During this Q&A interview, Crandall discussed the takeaways from her portion of an ACP conference presentation on current clinical guidelines in type 2 diabetes.

Meta-analysis of 11 phase 3 trials shows SGLT2 inhibitors reduce cardiovascular event risk by 9% across diverse patient populations.

In this episode, hosts discuss the STEP HFpEF DM trial and the need for fair allocation of incretin-based therapies with ongoing shortages and overwhelming demand.

The proposed insulin glargine biosimilar (Basalin) showed comparable immunogenicity, efficacy, and safety to the originator (Lantus) in a phase 3 equivalence trial.

Prices of nearly all insulins, SGLT2 inhibitors, and GLP1As could be reduced if robust generic or biosimilar manufacture were enabled.

In this endocrinology month in review for March 2024, we recap the most popular FDA news and pipeline updates as well as recognizing the 2-year anniversary of Diabetes Dialogue.

In this episode, hosts discuss GLP-1 RA use and CGM technology, updates in once-weekly insulins, the concept of continuous ketone monitoring, and practical application of artificial intelligence into care.

In this episode, all things AID from the 17th annual ATTD, including updates from Insulet Corporation and Omnipod, study data from the Control IQ algorithm, the SMASH study, and a peak into the future with the Neural Network AID algorithm.

In this episode, hosts discuss top news and updates in automated insulin delivery from ATTD 2024, with a focus on new data from the T1D Exchange and a read-out from the CRISTAL study.

In this episode, Neuen talks about the FLOW trial, the concept of 4 pillars of GDMT for CKD in type 2 diabetes, and how to approach sequencing of these therapies.

Jake Leach, COO of Dexcom, joins the podcast to discuss the historic clearance of the Stelo sensor and other updates in CGM from the company.

On March 08, 2024, the FDA approved semaglutide 2.4 mg (Wegovy) to reduce cardiovascular risk in adults with obesity or overweight and heart disease based on the SELECT trial.